Tarsus Pharmaceuticals (TARS) Change in Accured Expenses (2019 - 2026)

Tarsus Pharmaceuticals' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at $7.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 574.3% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $8.5 million (down 67.95% YoY), while the FY2025 annual figure was $2.0 million, down 94.82% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $7.7 million, up from -$35.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $30.5 million in Q3 2024, with the low at -$35.5 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is $2.0 million (2022), against an average of $3.3 million.
• Peak annual rise in Change in Accured Expenses reached 1039.45% in 2024, while the deepest fall reached 1694.09% in 2024.
• Tarsus Pharmaceuticals' Change in Accured Expenses stood at -$473000.0 in 2022, then soared by 638.9% to $2.5 million in 2023, then jumped by 390.51% to $12.5 million in 2024, then slumped by 383.84% to -$35.5 million in 2025, then jumped by 121.74% to $7.7 million in 2026.
• Business Quant data shows TARS's Change in Accured Expenses at $7.7 million in Q1 2026, -$35.5 million in Q4 2025, and $23.8 million in Q3 2025.